Orchestra BioMed Holdings (OBIO) Income towards Parent Company (2021 - 2026)
Orchestra BioMed Holdings (OBIO) reported Income towards Parent Company of -$22.9 million for Q1 2026, down 22.08% year-over-year from -$29.4 million in Q1 2025, and down 482.19% on a QoQ basis from $6.0 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 6 years of Income towards Parent Company data on file, last reported at -$22.9 million in Q1 2026.
- Quarterly Income towards Parent Company fell 22.08% year-over-year to -$22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.1 million (up 13.87% YoY) and the FY2025 annual result came in at -$53.0 million, up 13.11% from the prior year.
- Income towards Parent Company declined to -$22.9 million in Q1 2026 per OBIO's latest filing, from $6.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $6.0 million in Q4 2025 and bottomed at -$22.9 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$13.4 million (2024), against an average of -$12.9 million.
- The widest annual swing landed in 2022, when Income towards Parent Company tumbled 10577.39%; it then surged 137.08% in 2025.
- Tracing OBIO's Income towards Parent Company over 5 years: stood at -$9.8 million in 2022, then dropped by 15.72% to -$11.4 million in 2023, then sank by 42.05% to -$16.2 million in 2024, then surged by 137.08% to $6.0 million in 2025, then slumped by 482.19% to -$22.9 million in 2026.
- Per Business Quant, the three latest OBIO Income towards Parent Company figures stand at -$22.9 million (Q1 2026), $6.0 million (Q4 2025), and -$20.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.90 Mn |
| Dec 31, 2025 | 5.99 Mn |
| Sep 30, 2025 | -20.83 Mn |
| Jun 30, 2025 | -19.36 Mn |
| Mar 31, 2025 | -18.76 Mn |
| Dec 31, 2024 | -16.16 Mn |
| Sep 30, 2024 | -15.43 Mn |
| Jun 30, 2024 | -15.96 Mn |
| Mar 31, 2024 | -13.41 Mn |
| Dec 31, 2023 | -11.37 Mn |
| Sep 30, 2023 | -13.61 Mn |
| Jun 30, 2023 | -12.96 Mn |
| Mar 31, 2023 | -11.55 Mn |
| Dec 31, 2022 | -9.83 Mn |
| Sep 30, 2022 | -10.07 Mn |
| Jun 30, 2022 | -7.63 Mn |
| Mar 31, 2022 | -5.13 Mn |
| Dec 31, 2021 | -92,045.00 |
| Sep 30, 2021 | -94,445.00 |
| Jun 30, 2021 | -96,318.00 |
| Mar 31, 2021 | -111,948.00 |